文献速递头颈与中枢神经肿瘤

布帕利塞治疗携带磷脂酰肌醇3-激酶通路激活的复发性胶质母细胞瘤:一项开放标签、多中心、多臂、II期试验

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
PubMed 文献 · J Clin Oncol · 2019-02-04

这项开放标签、多中心、多臂II期试验评估了泛PI3K抑制剂布帕利塞在PI3K通路激活的复发性胶质母细胞瘤患者中的药代动力学、药效动力学和疗效。65例患者入组,队列1(n=15)术前接受布帕利塞7-13天,队列2(n=50)持续用药至进展或不可耐受毒性。结果显示单药疗效有限,6个月无进展生存率仅8%,中位无进展生存期1.7个月,虽脑穿透性良好但PI3K通路阻断不完全。

要点

  • 队列1中14例可评估患者有6例(42.8%)磷酸化AKT S473免疫组化评分降低,但对磷酸化核糖体蛋白S6 S235/236和增殖的影响不显著。
  • 队列2中50例患者仅4例(8%)达到6个月无进展生存,中位无进展生存期1.7个月(95% CI,1.4至1.8个月)。
  • 最常见的≥3级治疗相关不良事件为脂肪酶升高(7例[10.8%])、乏力(4例[6.2%])、高血糖(3例[4.6%])和ALT升高(3例[4.6%])。

核心结论

  • 布帕利塞在PI3K通路激活的复发性胶质母细胞瘤患者中单药疗效有限。
  • 尽管布帕利塞实现了显著的脑穿透,但缺乏临床疗效的原因是肿瘤组织中PI3K通路阻断不完全。
  • 综合结果提示,仍可能需要进一步研究能实现更完全通路抑制的PI3K抑制剂。

研究设计与样本

  • 研究为多中心、开放标签、多臂、II期试验,纳入首次或第二次复发的PI3K通路激活的胶质母细胞瘤患者。
  • 队列1为计划在进展后再次手术的患者,术前接受布帕利塞7至13天,以评估脑穿透和切除肿瘤组织中PI3K通路的调节。
  • 队列2为不适合再次手术的患者,接受布帕利塞直至进展或不可接受的毒性。
  • 布帕利塞100 mg每日一次口服,连续28天为一周期。
  • 主要终点:队列1为肿瘤组织中PI3K通路抑制和布帕利塞药代动力学;队列2为6个月无进展生存率(PFS6)。

主要发现

  • 队列1中,14例可评估患者中有6例(42.8%)达到磷酸化AKT S473免疫组化评分降低,但对磷酸化核糖体蛋白S6 S235/236和增殖的影响不显著。
  • 肿瘤与血浆药物浓度比为1.0。
  • 队列2中,50例患者中有4例(8%)达到6个月无进展生存,中位无进展生存期为1.7个月(95% CI,1.4至1.8个月)。
  • 最常见的≥3级治疗相关不良事件为脂肪酶升高(n=7[10.8%])、乏力(n=4[6.2%])、高血糖(n=3[4.6%])和ALT升高(n=3[4.6%])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Phosphatidylinositol 3-kinase (PI3K) signaling is highly active in glioblastomas. We assessed pharmacokinetics, pharmacodynamics, and efficacy of the pan-PI3K inhibitor buparlisib in patients with recurrent glioblastoma with PI3K pathway activation. METHODS: This study was a multicenter, open-label, multi-arm, phase II trial in patients with PI3K pathway-activated glioblastoma at first or second recurrence. In cohort 1, patients scheduled for re-operation after progression received buparlisib for 7 to 13 days before surgery to evaluate brain penetration and modulation of the PI3K pathway in resected tumor tissue. In cohort 2, patients not eligible for re-operation received buparlisib until progression or unacceptable toxicity. Once daily oral buparlisib 100 mg was administered on a continuous 28-day schedule. Primary end points were PI3K pathway inhibition in tumor tissue and buparlisib pharmacokinetics in cohort 1 and 6-month progression-free survival (PFS6) in cohort 2. RESULTS: Sixty-five patients were treated (cohort 1, n = 15; cohort 2, n = 50). In cohort 1, reduction of phosphorylated AKTS473 immunohistochemistry score was achieved in six (42.8%) of 14 patients, but effects on phosphoribosomal protein S6S235/236 and proliferation were not significant. Tumor-to-plasma drug level was 1.0. In cohort 2, four (8%) of 50 patients reached 6-month PFS6, and the median PFS was 1.7 months (95% CI, 1.4 to 1.8 months). The most common grade 3 or greater adverse events related to treatment were lipase elevation (n = 7 [10.8%]), fatigue (n = 4 [6.2%]), hyperglycemia (n = 3 [4.6%]), and elevated ALT (n = 3 [4.6%]). CONCLUSION: Buparlisib had minimal single-agent efficacy in patients with PI3K-activated recurrent glioblastoma. Although buparlisib achieved significant brain penetration, the lack of clinical efficacy was explained by incomplete blockade of the PI3K pathway in tumor tissue. Integrative results suggest that additional study of PI3K inhibitors that achieve more-complete pathway inhibition may still be warranted.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wen PY, Touat M, Alexander BM, et al. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019. PMID: 30715997. doi:10.1200/JCO.18.01207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。